118 related articles for article (PubMed ID: 28121355)
1. Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
Zhu BP; Guo ZQ; Lin L; Liu Q
Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):61-67. PubMed ID: 28121355
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer.
Wang Y; Zhang XF; Dai J; Zheng YC; Zhang MG; He JJ
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):559-562. PubMed ID: 23904377
[TBL] [Abstract][Full Text] [Related]
4. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
Lucarelli G; Rutigliano M; Bettocchi C; Palazzo S; Vavallo A; Galleggiante V; Trabucco S; Di Clemente D; Selvaggi FP; Battaglia M; Ditonno P
J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
[TBL] [Abstract][Full Text] [Related]
5. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer.
He JJ; Zhi K; Liu GF
Onkologie; 2011; 34(11):584-8. PubMed ID: 22104154
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
Perlmutter MA; Lepor H
Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
[TBL] [Abstract][Full Text] [Related]
10. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
13. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.
Carlinfante G; Vassiliou D; Svensson O; Wendel M; Heinegård D; Andersson G
Clin Exp Metastasis; 2003; 20(5):437-44. PubMed ID: 14524533
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
17. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
18. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
19. Optimal measure of PSA kinetics to identify prostate cancer.
Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
